

NCIC CLINICAL TRIALS GROUP

GASTROINTESTINAL

DISEASE SITE COMMITTEE MEETING AGENDA

OPEN SESSION

Venue: Delta Chelsea Hotel
Room: Churchill (A)
Date: Sunday, April 29th, 2007
Time: 8:30 am – 3:30 pm
Chair: Dr. Malcolm Moore

- 8:30 am **WELCOME AND INTRODUCTION** Dr. M. Moore
- 8:40 am **COLON DISEASE ORIENTED WORKING GROUP** Dr. D. Jonker, Dr. S. Gill

CLOSED TRIALS

CO.17: A Phase III Randomized Study of Cetuximab (ErbixTM, C225) and Best Supportive Care versus Best Supportive Care in Patients with Pretreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Positive Colorectal Carcinoma

Main Trial Results Dr. D. Jonker

Quality of Life Analyses Dr. H.J. Au

Proposed Economic Analyses Dr. H.J. Au / Dr. N. Mittman

ENDORSED CTSU TRIALS

CRC.2 (NCCTG N0147): A Randomized Phase III Trial of Irinotecan (CPT-11) and/or Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer

Dr. S. Gill

CRC.3 (ECOG E5202): A Randomized Phase III Study Comparing 5-FU Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers.

Dr. C. Butts

APPROVED TRIALS IN DEVELOPMENT

IND.171: A Phase I, Open-Label, Dose-Seeking Study of AZD2171 Given Daily Orally in Combination with Selected Standard Chemotherapy Regimens (CT) in Patients with Advanced Incurable Non-Small Cell Lung Cancer (NSCLC) or Colorectal Cancer

Dr. D. Jonker

CO.18: A Phase II Study of AZD2171 and Capecitabine versus Capecitabine Alone as 1st Line Therapy in Patients with Metastatic Colorectal Cancer

Dr. C. Cripps

APPROVED TRIALS IN DEVELOPMENT (CONTINUED)

CO.20: A Phase III Randomized Study of BMS582664 and Cetuximab (ErbixTM) versus Cetuximab in Patients with Pretreated Metastatic Colorectal Carcinoma

Dr. L. Siu

10:15 am **REFRESHMENT BREAK**10:30 am **COLON DISEASE ORIENTED WORKING GROUP (CONTINUED)**

Dr. D. Jonker, Dr. S. Gill

NEW TRIALS / CONCEPTS / PROPOSALS

TBA

11:00 am **NEUROENDOCRINE TUMOUR DISEASE ORIENTED WORKING GROUP**

Dr. L. Siu, Dr. W. Kocha

NEW TRIALS / CONCEPTS / PROPOSALS

TBA

11:20 am **RECTAL DISEASE ORIENTED WORKING GROUP**

Dr. J. Brierley, Dr. N. Baxter

ENDORSED CTSU TRIALS

CRC.4 (ECOG E5204): Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation.

Dr. J. Brierely

NEW TRIALS / CONCEPTS / PROPOSALS

TBA

11:50 am **IND REPORT**

Dr. Ralph Wong

12:00 pm **LUNCH**1:00 pm **ESOPHAGEAL DISEASE ORIENTED WORKING GROUP**

Dr. Rebecca Wong, Dr. C. Kollmannsberger

ACTIVE TRIALS

ES.2 (TROG 03.01): A Randomised Phase III Study in Advanced Oesophageal Cancer to Compare Quality of Life and palliation of Dysphagia in Patients Treated with Radiotherapy versus Chemo-Radiotherapy

Dr. Rebecca Wong

1:00 pm **ESOPHAGEAL DISEASE ORIENTED WORKING GROUP (CONTINUED)**

ENDORSED CTSU TRIALS

GAC.1 (CALGB-80101): A Phase III Trial of Adjuvant Chemoradiation After Resection of Gastric Or Gastroesophageal Adenocarcinoma

Dr. G. Bjarnason

NEW TRIALS / CONCEPTS / PROPOSALS

TBA

2:00 pm **PANCREATIC DISEASE ORIENTED WORKING GROUP**

Dr. M. Moore, Dr. S. Gallinger

CLOSED TRIALS

PAC.1 (SWOG-S0205): A Randomized Placebo Controlled Study of Cetuximab plus Gemcitabine in Patients with Locally Advanced, Unresectable or Metastatic Pancreatic Cancer

Dr. Ralph Wong

ACTIVE TRIALS

PA.2 (ESPAC-3): Adjuvant Chemotherapies in Resectable Pancreatic Cancer

Dr. M. Moore

NEW TRIALS / CONCEPTS / PROPOSALS

TBA

2:45 pm **HEPATOBIILIARY DISEASE ORIENTED WORKING GROUP**

Dr. J. Knox, Dr. O. Bathe

APPROVED TRIALS IN DEVELOPMENT

BI.1: A Phase III Study of Gemcitabine Plus Capecitabine (GEMCAP) versus Gemcitabine Alone in Advanced Biliary Cancer

Dr. J. Knox

NEW TRIALS / CONCEPTS / PROPOSALS

TBA

3:15 pm **CLOSING REMARKS & ADJOURNMENT**

Dr. M. Moore

3:30 pm **CLOSED SESSION: GI EXECUTIVE MEETING**

Dr. M. Moore